STOCK TITAN

Insmed (INSM) Stock News, Mar-Jun 2023

INSM NASDAQ

Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.

Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
AI
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company dedicated to treating serious rare diseases, will host an investor and analyst event titled "The Future of Rare at Insmed" on May 8, 2023, from 8:00 a.m. to 12:00 p.m. ET in New York. The event will focus on Insmed's early-stage research programs and feature presentations from management and research leaders discussing their innovative platforms. The company aims to develop at least six new investigational new drug applications by 2025. A live webcast will be available on their website, with a replay accessible 30 minutes after the event's conclusion. Insmed's mission includes advancing therapies targeting unaddressed medical needs in rare pulmonary disorders and other serious conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
conferences
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced it will release its first quarter 2023 financial results on May 4, 2023. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update.

Participants can join the call by dialing (833) 470-1428 for U.S. calls or (929) 526-1599 for international calls, using access code 468531. The call will also be available via a live webcast on Insmed's website.

A replay will be accessible after the call, lasting until June 3, 2023. Insmed is dedicated to treating serious and rare diseases with its approved therapies and an expanding pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences earnings date
-
Rhea-AI Summary

On April 6, 2023, Insmed (Nasdaq: INSM) announced the granting of inducement awards to 24 new employees as per NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase a total of 182,880 shares of common stock at an exercise price of $17.37, which corresponds to the closing trading price on the date of grant, April 3, 2023. The options feature a 10-year term and a four-year vesting schedule, with shares vesting incrementally over that period. Insmed is focused on transforming the lives of patients with serious and rare diseases, with its first commercial product approved in multiple regions to treat a chronic lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) has announced the completion of adult patient enrollment in its pivotal ASPEN study for brensocatib, a first-in-class treatment candidate for bronchiectasis. The Phase 3 study has enrolled over 1,700 patients aged 12 to 85 years, randomized into three groups for a 52-week treatment period. Topline data is expected in Q2 2024. Brensocatib, which has received Breakthrough Therapy Designation from the FDA, targets a market with no approved treatments and aims to alleviate the severe symptoms of bronchiectasis. The ongoing adolescent enrollment will not impact planned regulatory submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
Rhea-AI Summary

Insmed, a biopharmaceutical company, announced eight presentations focusing on lung diseases at the American Thoracic Society (ATS) 2023 International Conference, scheduled for May 19-24, 2023, in Washington, D.C. Key highlights include:

  • A qualitative interview study on amikacin liposome inhalation suspension (ARIKAYCE)
  • Subgroup analysis of the Phase 2 WILLOW study on brensocatib in bronchiectasis patients
  • Data on the hospitalization burden for patients with chronic obstructive pulmonary disease (COPD) and nontuberculous mycobacterial lung disease.

Insmed aims to address significant challenges in treating serious and rare lung diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
conferences

FAQ

What is the current stock price of Insmed (INSM)?

Insmed (INSM) last closed at $141.33.

What is the market cap of Insmed (INSM)?

The market cap of Insmed (INSM) is approximately $31.0B.